FDA Accepts Oyster Point's Varenicline Nasal Spray Application For Review In Dry Eye Disease

by Vandana Singh, Benzinga Editor

March 2, 2021 8:36 AM | 1 min read |

The FDA has accepted Oyster Point Pharma Inc's (NASDAQ: OYST) marketing application for review. It seeks approval for OC-01 (varenicline) nasal spray to treat signs and symptoms of dry eye disease.
The target date is October 17.
At present, FDA has stated that it does not intend to hold an advisory committee meeting for this application.
OC-01 (varenicline) nasal spray is a highly selective cholinergic agonist.
Price Action: OYST shares closed 2.2% higher at $20.25 on Monday.

Posted In: Biotech News Health Care Small Cap FDA General dry eye disease

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.